Furthermore, mutations in cancer therapeutic targets can greatly affect drug sensitivity, and mutation-driven resistance is common in cancer, such as resistance to HER2 and its inhibitors, and resistance to ALK and different generations of ALK inhibitors (7). The gene discussed is ERBB2; the disease is cancer.